Browsing Tag
vispa-cel
1 post
Why is Caribou Biosciences ending CAR-T development before a planned phase 3 trial?
Caribou Biosciences is winding down its allogeneic CAR-T programmes and sharply reducing its workforce after financing constraints overtook clinical progress, leaving $113.8 million of mid-year liquidity and its genome-editing assets at the centre of a strategic review.